Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Pediatric Infectious Disease Research Center, Tehran University of Medical Science, Tehran, Iran.
World J Pediatr. 2021 Feb;17(1):71-78. doi: 10.1007/s12519-020-00397-7. Epub 2021 Jan 2.
Coronavirus disease 2019 (COVID-19) is the current pandemic disease without any vaccine or efficient treatment to rescue the patients. Underlying diseases predispose the patients to a more severe disease and to a higher mortality rate. However, little evidence exists about COVID-19 outcomes in the pediatric population with congenital heart disease (CHD). Here, we report nine children with COVID-19 and concomitant CHD.
Our study included nine children with COVID-19 and concomitant CHD who were admitted to Children Medical Center Hospital during March and April 2020. The patients were classified based on the final outcome (death), and their clinical sign and symptoms, type of CHD, and drugs administered were compared.
Among the nine patients, two died and we compared different characteristics, laboratory results and clinical findings of these cases based on the mortality. The deceased patients had severe types of CHD, worse arterial blood gases, severe clinical symptoms, higher mean level of partial thromboplastin time and C-reactive protein, and required more medications.
The present study showed that the general consideration of mild COVID-19 in children does not include patients with CHD and that it is necessary to pay greater attention to children with CHD to determine guidelines for treatment of COVID-19 in these children. Owing to the scarcity of CHD and COVID-19, we reported only nine cases. However, further studies are highly required in this regard.
2019 年冠状病毒病(COVID-19)是目前没有疫苗或有效治疗方法来救治患者的大流行病。基础疾病使患者更容易患上更严重的疾病和更高的死亡率。然而,关于伴有先天性心脏病(CHD)的儿科人群中 COVID-19 结局的证据很少。在这里,我们报告了 9 例伴有 COVID-19 和 CHD 的儿童病例。
我们的研究包括 2020 年 3 月至 4 月期间在儿童医院收治的 9 例伴有 COVID-19 和 CHD 的儿童患者。根据最终结局(死亡)对患者进行分类,并比较他们的临床症状和体征、CHD 类型以及给予的药物。
在 9 例患者中,有 2 例死亡,我们根据死亡率比较了这些病例的不同特征、实验室结果和临床发现。死亡患者患有严重类型的 CHD,动脉血气更差,临床症状更严重,部分凝血活酶时间和 C 反应蛋白的平均水平更高,需要更多的药物治疗。
本研究表明,儿童 COVID-19 的一般轻度考虑不包括 CHD 患者,有必要更加关注伴有 CHD 的儿童,以确定这些儿童 COVID-19 治疗指南。由于 CHD 和 COVID-19 的稀缺性,我们仅报告了 9 例病例。然而,在这方面需要进一步的研究。